Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies

Immunotherapy. 2019 Jul;11(10):851-857. doi: 10.2217/imt-2019-0074. Epub 2019 Jun 4.

Authors

Roman H Khadka^{1

2}, Reona Sakemura³, Saad S Kenderian^{2

3}, Aaron J Johnson^{2

4}

Affiliations

¹ Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
² Department of Immunology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
³ Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
⁴ Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

PMID: 31161844
DOI: 10.2217/imt-2019-0074

No abstract available

Keywords: BiTE; CAR T cells; CRS; bispecific T cell engager; chimeric antigen receptor; cytokine release syndrome; immunotherapy; neurotoxicity.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Cytokine Release Syndrome* / immunology
Cytokine Release Syndrome* / pathology
Cytokine Release Syndrome* / therapy
Humans
Immunotherapy*
T-Lymphocytes* / immunology
T-Lymphocytes* / pathology

Grants and funding

R01 NS103212/NS/NINDS NIH HHS/United States